MBX — MBX Biosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1776111 ·
Last close
$53.10
Market Cap
$2.64B
52W High
$72.64
52W Low
$25.11
ADV30
566,150
Next earnings
2026-11-12
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -66,343,000 -62,421,000 500,618,000 161,691,000 27,671,000
Jun 2026 0 — -40,931,000 -37,095,000 435,909,000 54,124,000 26,370,000
Mar 2026 0 — -27,265,000 -23,517,000 452,701,000 45,214,000 14,945,000
Dec 2025 0 — -25,795,000 -22,062,000 385,144,000 75,289,000 15,921,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-96,008,000
Investing CF
$-155,027,000
Financing CF
$189,806,000
CapEx
$-3,322,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.06
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-347,509,000
Inventory
—
Receivables
$3,231,000
ST Investments
$319,903,000
EBIT TTM
$-160,334,000
Pretax Income TTM
$-145,095,000
Interest Exp TTM
—
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -98,055,000 -86,971,000 385,144,000 15,921,000 369,223,000 -79,949,000
Dec 2024 0 -68,194,000 -61,922,000 268,535,000 11,093,000 257,442,000 -54,681,000
Dec 2023 0 -35,311,000 -32,563,000 84,180,000 156,648,000 -72,468,000 -31,978,000
Dec 2022 0 -25,161,000 -26,135,000 45,095,000 87,700,000 -42,605,000 -23,122,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-104,292,000
OpCashFlow TTM
—
Assets (Latest)
$435,909,000
Forward EPS
$-4.35

Max Pain — expiry 2026-12-18

max pain strike: $60.00 · spot: $53.42 · call oi: 2,139 · put oi: 442
Expected Move to 2026-12-18: ±$18.60 (34.82%) — implied range $34.82 – $72.02 · ATM straddle on $55.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IDYA IDEAYA Biosciences, Inc. $2.65B $27.40 —
XNCR Xencor Inc $2.59B $34.50 —
HCM HUTCHMED (China) Ltd $2.50B $14.40 —
ZLAB Zai Lab Ltd $2.91B $23.53 —
RCUS Arcus Biosciences, Inc. $2.36B $16.39 —

News headlines (Yahoo Finance, 1h cache)

Norwest Announces $4 Billion Global, Multi-Stage Fund
2026-11-12 11:00 · Yahoo
MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
2026-11-09 21:01 · Yahoo
MBX Biosciences to Participate in Upcoming November Investor Conferences
2026-10-13 12:00 · Yahoo
Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?
2026-10-10 04:19 · Yahoo
MBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%
2026-10-10 00:18 · Yahoo
MBX Biosciences to Participate in Upcoming Investor Conferences
2026-09-09 12:00 · Yahoo
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
2026-08-27 12:00 · Yahoo
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-06 12:00 · Yahoo
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
2026-07-13 20:15 · Yahoo
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
2026-06-12 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.